Everything below concerns immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-05. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
He had to leave the game after the seventh with a pulled back muscle, but he was back in action four days later. He won just twice more all season, as he dealt with back problems. On August 1, he again struck out eight Phillies but received a no decision, as he was removed with one out in the ninth and the game tied 1–1. The Cardinals won on a Stan Musial home run in the bottom of the inning. In 31 games (30 starts), he had a 13–10 record, a 4.20 ERA, 108 strikeouts, and 89 walks in 201+1⁄3 innings pitched. By 1960, Mizell had recovered from his back issues. He began the season with the Cardinals but only won one of his first nine games, posting a 4.55 ERA. By this point, the Cardinals felt that he had never attained his full potential. On May 28, they traded him and Dick Gray to the Pirates for Ed Bauta and Julián Javier, the latter of whom would reach two All-Star Games and win two World Series with the Cardinals over the next decade.
=== In relation with experience === Thomas Nagel has said that "There are elements which, if added to one's experience, make life better; there are other elements which if added to one's experience, make life worse. But what remains when these are set aside is not merely neutral: it is emphatically positive." Experiences are central to a proposed dimension of well-being called psychological richness. This additional dimension of well-being was proposed as an empirically supported expansion to the hedonic vs. eudaimonic well-being dichotomy. Whereas hedonic well-being can be measured via life satisfaction, and eudaimonic well-being can be measured via one's perceptions of the meaning of their life, psychological richness is measured via characteristic experiences. Psychological richness is cultivated through having psychologically rich experiences, which are characterized as varying, interesting, novel, challenging, and perspective-changing, as subjectively measured by the experiencer. One line of evidence for this comes from studies conducted with college students, where students who went on trips (new and unusual experiences), whether they be short excursions or semester-length study abroad programs, reported increased psychological richness, but not increases in happiness or meaning (Oishi et al., 2021). In contrast to hedonic well-being, which is thought to result in personal satisfaction, and eudaimonic well-being, which is thought to result in societal contribution, psychological richness is thought to result in wisdom.
== Fiber coatings == The coating on the SPME fiber can be selected to improve sensitivity for specific analytes of interest; ideally the sorbent layer will have a high affinity for the target analytes. There are many commercially available SPME fiber coatings that are combinations of polydimethylsiloxane, divinylbenzene, Carboxen, polyacrylate, and polyethylene glycol. However, one downside to many of the commercially available SPME fibers is that they tend to be physically brittle due to their composition. Depending on the characteristics of the target analytes, certain properties of the coating improve extraction such as polarity, thickness, and surface area. The sample matrix can also influence the fiber coating selection. Based on the sample and analytes of interest, the fiber may need to tolerate direct immersion as opposed to a headspace extraction. In one of the study the fiber coating method significantly enhances the performance of SPME by ensuring a high binding capacity and improved mass transfer efficiency. By preventing the ingress of the polymeric adhesive matrix into the pores of the sorbent particles, the method allows for faster adsorption and desorption times, which is crucial for high-throughput applications. Metal–organic frameworks (MOFs) have been investigated as sorbent materials for SPME coatings because their pore dimensions and surface functional groups can be modified to alter extraction affinity and selectivity.
=== RNA sequencing === RNA sequencing was one of the earliest forms of nucleotide sequencing. The major landmark of RNA sequencing is the sequence of the first complete gene and the complete genome of Bacteriophage MS2, identified and published by Walter Fiers and his coworkers at the University of Ghent (Ghent, Belgium), in 1972 and 1976. Traditional RNA sequencing methods require the creation of a cDNA molecule which must be sequenced.
== Strong bases == A strong base is a base that is quantitatively protonated upon exposure to water. This complete protonation is a result of the leveling effect. The term "strong base" can lead to confusion, since in this case "strong" is a category of base rather than a qualitative description. For example, guanidine is a very basic molecule, but it does not meet the definition of a strong base because it is not fully protonated by water. Common examples of strong bases include hydroxides of alkali metals and alkaline earth metals, like sodium hydroxide and calcium hydroxide, respectively. Due to their low solubility, some bases, such as alkaline earth hydroxides, can be used when the solubility factor is not taken into account. One advantage of this low solubility is that "many antacids were suspensions of metal hydroxides such as aluminium hydroxide and magnesium hydroxide"; compounds with low solubility and the ability to stop an increase in the concentration of the hydroxide ion, preventing the harm of the tissues in the mouth, oesophagus, and stomach. As the reaction continues and the salts dissolve, the stomach acid reacts with the hydroxide produced by the suspensions. Strong bases hydrolyze in water completely due to the leveling effect. In this process, the water molecule acts as an acid to protonate the base, resulting in the formation of a hydroxide anion. Under anhydrous conditions, some strong bases can even deprotonate weakly acidic C–H bonds. Here is a list of several strong bases:
Sources: en.wikipedia.org
==== Background ==== In spring 1985 Heseltine displayed little interest in Westland helicopters when approached by Tebbit (then Secretary of State for Trade and Industry) at the time of Alan Bristow's bid for the company, as plenty of American helicopters were available to meet Britain's defence requirements. He attended two meetings about the company's future in June 1985, chaired by Thatcher. Heseltine, who had a poor opinion of Westland's management, was willing to inject £30 million, provided the Treasury contributed half. The idea was not approved. Heseltine took against the new chairman Sir John Cuckney's plan that Westland merge with United Technologies Corporation, of which the US company Sikorsky was a subsidiary, after realising that Westland would probably become responsible for assembling the Sikorsky UH-60 Black Hawk helicopter, which the Ministry of Defence would then be under great pressure to buy, whereas he preferred Westland to go into receivership so that GEC and British Aerospace could buy the viable parts of the business. In mid-October Heseltine suggested a European consortium (which would include French Aérospatiale, German MBB and Italian Agusta). The new Trade and Industry Secretary Leon Brittan at first urged Thatcher to consider a European option (Heseltine later said Brittan preferred this option, although Brittan denied this). The Government was officially neutral (i.e. arguing that it was a matter for Westland directors and shareholders) but by November Heseltine was pushing the European option hard.
As an isolate - through the process of wet fractionation which produces a high protein concentration As a concentrate - through the process of dry fractionation which produces a low protein concentration In textured form, which is when it is used in food products as a substitute for other products, such as meat alternatives Pea protein has low allergenicity and high nutritional value. It is common as a source of protein in vegan and vegetarian food, and in protein supplement products.
The causes of hirsutism can be divided into endocrine imbalances and non-endocrine etiologies. It is important to begin by first determining the distribution of body hair growth. If hair growth follows a male distribution, it could indicate the presence of increased androgens or hyperandrogenism. However, there are other hormones not related to androgens that can lead to hirsutism. A detailed history is taken by a provider in search of possible causes for hyperandrogenism or other non-endocrine-related causes. If the distribution of hair growth occurs throughout the body, this is referred to as hypertrichosis, not hirsutism.
== Radiation-induced hair loss == Radiation induces hair loss through damage to hair follicle stem cell progenitors and alteration of keratin expression. Radiation therapy has been associated with increased mucin production in hair follicles. Studies have suggested electromagnetic radiation as a therapeutic growth stimulant in alopecia.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.